Agios Pharmaceuticals (AGIO) Assets Average (2013 - 2026)

Agios Pharmaceuticals has reported Assets Average for 14 years, with the latest figure at $1.2 billion in Q1 2026.

• For the quarter ending Q1 2026, Assets Average fell 22.88% year-over-year to $1.2 billion; the trailing twelve-month figure through Mar 2026 stood at $1.2 billion (down 22.88% YoY), and the FY2025 full-year result was $1.5 billion, up 13.85% from the prior year.
• Assets Average for Q1 2026 stood at $1.2 billion, down from $1.3 billion in the prior quarter.
• The five-year high for Assets Average was $1.7 billion in Q4 2024, with the low at $811.4 million in Q2 2024.
• Historically, Assets Average has averaged $1.3 billion across 5 years, with a median of $1.2 billion in 2026.
• Annual changes were most pronounced in 2022 — Assets Average slumped 40.68% — and 2025, when it jumped 86.52%.
• Agios Pharmaceuticals' Assets Average stood at $1.2 billion in 2022, then retreated by 19.62% to $972.2 million in 2023, then soared by 77.69% to $1.7 billion in 2024, then decreased by 22.35% to $1.3 billion in 2025, then fell by 7.48% to $1.2 billion in 2026.
• The last three Assets Average figures came in at $1.2 billion (Q1 2026), $1.3 billion (Q4 2025), and $1.4 billion (Q3 2025), per Business Quant data.